Amneal Sets $200m Sales Ambition For Biosimilar Trio

Looking To Expand Portfolio With Licensing Deals For Early-Entry Opportunities

200m road marking
Amneal has revealed a $200m “peak” sales estimate for its trio of biosimilars • Source: Shutterstock

More from Biosimilars

More from Products